BioCentury
ARTICLE | Tools & Techniques

BioNTech tackles solid tumors by pairing CAR Ts with RNA vaccines

How BioNTech aims to solve some of the biggest challenges of bringing CAR T cells to solid tumors

January 4, 2020 2:07 AM UTC
Updated on Jan 4, 2020 at 2:12 AM UTC

BioNTech is marrying two of its core technologies -- RNA therapeutics and engineered cell therapies -- to solve some of the biggest challenges of bringing CAR T cells to solid tumors.

It believes that together, the technologies will improve the in vivo expansion and persistence of the cells, keeping large enough numbers of cells around for long enough to be effective in the solid tumor setting. ...

BCIQ Company Profiles

BioNTech SE